Table 1 |
|||
|
Baseline characteristics |
|||
|
Patients, number |
21 |
||
|
Gender male/female |
1 |
/ |
20 |
|
Age, years |
52 |
± |
18 |
|
Height, cm |
165 |
± |
6 |
|
Weight, kg |
68 |
± |
11 |
|
WHO functional class, number (%) |
|||
|
II |
9 |
(43) |
|
|
III |
7 |
(33) |
|
|
IV |
5 |
(24) |
|
|
Lung function |
|||
|
TLCO, % |
55 |
± |
18 |
|
FEV1%VC, % |
78 |
± |
7 |
|
pO2, mmHg |
69 |
± |
12 |
|
Mean 6-minute-walking distance, meter |
|||
|
386 |
± |
121 |
|
|
Differential Diagnosis, number (%) |
|||
|
Systemic sclerosis |
8 |
(43%) |
|
|
Systemic lupus |
7 |
(33%) |
|
|
MCTD |
2 |
(10%) |
|
|
Others |
4 |
(14%) |
|
|
Cardiac catherization |
|||
|
Pulmonary artery pressure, mmHg |
49 |
± |
13 |
|
Pulmonary vascular resistance, dyn×sec×cm-5 |
789 |
± |
498 |
|
Right atrium pressure, mmHg |
7 |
± |
3 |
|
Pulmonary artery oxygen saturation, % |
62 |
± |
10 |
|
PCWP, mmHg |
10 |
± |
5 |
|
Cardiac index, L×min×m-2 |
2.6 |
± |
0.6 |
|
PAH-targeted medication, number (%) |
|||
|
Endothelin receptor antagonists |
12 |
(57%) |
|
|
Phosphodiesterase-5-Inhibitors |
15 |
(71%) |
|
|
Prostanoids inhaled |
3 |
(14%) |
|
|
Prostanoids intravenous |
1 |
(5%) |
|
|
Calcium channel blockers |
2 |
(10%) |
|
|
Soluble guanyl cyclase-stimulator |
3 |
(14%) |
|
|
Combination therapy, number (%) |
|||
|
Monotherapy |
8 |
(38%) |
|
|
Dual therapy |
10 |
(48%) |
|
|
Triple therapy |
3 |
(14%) |
|
|
|
|||
|
Results are presented as mean ± standard deviation unless stated otherwise WHO: World Health Organization; FEV1%VC: forced expiratory volume in one second/vital capacity; TLCO: carbon monoxide transfer factor; pO2: partial oxygen pressure; PCWP: pulmonary capillary wedge pressure; MCTD: mixed connective tissue disease. |
|||
|
Grünig et al. Arthritis Research & Therapy 2012 14:R148 doi:10.1186/ar3883 |
|||
